Molecular Formula | C24H36N4O6S2 |
Molar Mass | 540.7 |
Density | 1.174 |
Melting Point | 219-224°C |
Boling Point | 942.8±65.0 °C(Predicted) |
Flash Point | 524°C |
Solubility | Soluble in DMSO (up to 10 mg/ml). |
Vapor Presure | 0mmHg at 25°C |
Appearance | powder |
Color | white to beige |
pKa | 11.33±0.60(Predicted) |
Storage Condition | -20°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. |
Refractive Index | 1.529 |
In vitro study | Romidepsin inhibited the growth of the NSCLC cell line with IC50 ranging from 1.3 ng/mL to 4.9 ng/mL. Romidepsin can reduce the IC50 value of Erlotinib to NSCLC cell line and increase the sensitivity of NSCLC cell line to Erlotinib. Rmidepsin treatment for 72 hours inhibited the growth of 6/6 human NB tumor cell lines, whereas the NIH3T3 cell line was unaffected. Romidepsin showed selective cytotoxicity against single-copy or N-myc-copy NB cell lines as well as cell lines containing normal or mutated p53 and Alk mutants, and this toxicity was of a dose-dependent nature. |
In vivo study | Compared with the PBS-treated control group, Erlotinib and Romidepsin alone inhibited the xenograft growth of NCI-H1299 cell lines to 72% and 43%, respectively, but this was not statistically significant. Only when the two drugs were used in combination, the growth was significantly inhibited, and the growth was inhibited to 28%. In immunocompromised mice, Romidepsin inhibits the growth of subcutaneous NB xenografts, and this inhibition has a dose-dependent character. In addition, Romidepsin induces the expression of certain genes, such as p21 and p75, as well as NTRK (TrkA), in tumor tissues of NB patients. |
RTECS | YV9399000 |
HS Code | 29349990 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.849 ml | 9.247 ml | 18.495 ml |
5 mM | 0.37 ml | 1.849 ml | 3.699 ml |
10 mM | 0.185 ml | 0.925 ml | 1.849 ml |
5 mM | 0.037 ml | 0.185 ml | 0.37 ml |